SCHEMBL13076

SCHEMBL13076

C[C@@H]1CCCN(C)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3259496 1.00
SCHEMBL10017892 1.00
SCHEMBL81240 1.00
SCHEMBL8541894 0.97
Hydrochloric Acid SCHEMBL30330929 0.97
SCHEMBL19185686 0.95 ALDH1A1 (0.38)
SCHEMBL15038217 0.92
SCHEMBL19533310 0.92
SCHEMBL6853488 0.92
SCHEMBL23967079 0.91 NCF1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024151557-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-07-18 WO disclosed
WO-2024124002-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS THIRD HARMONIC BIO, INC. (US) 2024-06-13 WO disclosed
WO-2024077244-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS HOTSPOT THERAPEUTICS, INC. (US) 2024-04-11 WO disclosed
US-20240067627-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS AG (CH) 2024-02-29 US disclosed
WO-2024009232-A1 SUBSTITUTED N-(PYRIDIN-2-YL)ACETAMIDE DERIVATIVES AS CDK12/13 INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2024-01-11 WO disclosed
US-11834407-B2 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-12-05 US disclosed
US-20230365561-A1 BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) 2023-11-16 US disclosed
WO-2023219952-A1 MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2023-11-16 WO disclosed
WO-2023220715-A1 OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2023-11-16 WO disclosed
US-20230348424-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. 2023-11-02 US disclosed
US-20100249049-A1 ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME MIYAZAKI HIROSHI 2010-09-30 US disclosed
WO-2010106333-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-09-23 WO disclosed
WO-2009125870-A1 PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS. MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 WO disclosed
US-20090012062-A1 Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases BIOFOCUS DISCOVERY LTD. (GB) 2009-01-08 US disclosed
US-20090012062-A1 Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases BIOFOCUS DISCOVERY LTD. (GB) 2009-01-08 US disclosed
WO-2007126362-A1 COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA ASTRAZENECA AB (SE) 2007-11-08 WO disclosed
US-20070225296-A1 Arylalkylamine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-09-27 US disclosed
US-20070225296-A1 Arylalkylamine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-09-27 US disclosed
WO-2007081571-A2 CETP INHIBITORS MERCK & CO., INC. (US) 2007-07-19 WO disclosed
EP-1757582-A1 ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF TANABE SEIYAKU CO., LTD. (JP) 2007-02-28 EP disclosed